We used the average VI of a non-tumor ROI to approximate the signal returned by freely flowing contrast (ffc) for both anti-SFRP2 and IgY targeted contrast, and plotted the ffc-corrected TICs in Fig 3E. This evidence concerns the gene SFRP2 and neoplasm.